SCHEMBL5714919

SCHEMBL5714919

Cc1ccnc(Cc2ccc(OC(=O)N3CCN(CCCc4cccc(C)n4)CC3)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FAAH O00519 6/20 0.42
HRH2 P25021 3/20 0.41
HRH1 P35367 3/20 0.41
ADORA3 P0DMS8 1/20 0.41
HTR2A P28223 1/20 0.41
HTR7 P34969 1/20 0.41
OPRM1 P35372 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
MGLL Q99685 2/20 0.40
TP53 P04637 2/20 0.39
LMNA P02545 1/20 0.39
GPR4 P46093 1/20 0.38
DRD2 P14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714641 0.95 TP53 (0.43) FAAHHRH2HRH1TP53LMNA
SCHEMBL5714848 0.93 FAAH (0.42) FAAHHRH2HRH1ADORA3HTR2A
SCHEMBL5714281 0.90 TP53 (0.46) FAAHHRH2HRH1ADORA3HTR2A
SCHEMBL5715388 0.90 TP53 (0.48) FAAHHRH2HRH1ADORA3HTR2A
SCHEMBL5714867 0.90 SIGMAR1 (0.44) FAAHHRH2HRH1ADORA3HTR2A
SCHEMBL5714865 0.89 KDM4E (0.45)
SCHEMBL5715122 0.89 TP53 (0.48) FAAHADORA3HTR2AHTR7OPRM1
SCHEMBL5715224 0.88 TP53 (0.42) FAAHHRH2HRH1TP53LMNA
SCHEMBL5714552 0.87 SIGMAR1 (0.41) FAAHHRH2HRH1ADORA3HTR2A
SCHEMBL5714850 0.86 ADORA3 (0.40) FAAHHRH2HRH1ADORA3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL FAAH 219/4885HRH2 589/4885HRH1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.